Pfiz­er says IRA im­pact will be 'mod­est,' maps out R&D pri­or­i­ty changes

De­spite be­ing an ear­ly crit­ic of the In­fla­tion Re­duc­tion Act, Pfiz­er told in­vestors on Mon­day that the leg­is­la­tion is like­ly to have a “mod­est” im­pact on the com­pa­ny over­all.

Pfiz­er’s CEO Al­bert Bourla was one of sev­er­al phar­ma ex­ec­u­tives to con­demn the IRA’s Medicare ne­go­ti­a­tion pro­vi­sions ear­ly on, call­ing it “ne­go­ti­a­tion with a gun to your head” in a live-streamed Reuters in­ter­view last May. But it ap­pears that Pfiz­er is com­ing to terms with the new law.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER